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Abstract Retinoic acid (RA) is a potent regulator of gene
transcription via its activation of a set of nuclear receptors
controlling transcriptional activation. Precise maintenance
of where and when RA is generated is essential and achieved
by local expression of synthetic and catabolic enzymes. The
catabolic enzymes Cyp26a1 and Cyp26b1 have been studied
in detail in the embryo, where they limit gradients of RA that
form patterns of gene expression, crucial for morphogenesis.
This paracrine role of RA has been assumed to occur in most
tissues and that the RA synthetic enzymes release RA at a site
distant from the catabolic enzymes. In contrast to the
embryonic CNS, relatively little is known about RA meta-
bolism in the adult brain. This study investigated the distri-
bution of Cyp26a1 and Cyp26b1 transcripts in the rat brain,
identifying several novel regions of expression, including
the cerebral cortex for both enzymes and striatum for
Cyp26b1. In vivo use of a new and potent inhibitor of the
Cyp26 enzymes, ser 2–7, demonstrated a function for
endogenous Cyp26 in the brain and that hippocampal RA
levels can be raised by ser 2–7, altering the effect of RA on
differential patterning of cell proliferation in the hip-
pocampal region of neurogenesis, the subgranular zone. The
expression of CYP26A1 and CYP26B1 was also investigated
in the adult human brain and colocalization of CYP26A1 and
the RA synthetic enzyme RALDH2 indicated a different,
autocrine role for RA in human hippocampal neurons.
Studies with the SH-SY5Y human neuroblastoma cell line
implied that the co-expression of RA synthetic and catabolic
enzymes maintains retinoid homeostasis within neurons.
This presents a novel view of RA in human neurons as part of
an autocrine, intracellular signaling system.
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Introduction
Retinoic acid (RA), synthesized from vitamin A through a
series of oxidative steps, is a lipid regulator of transcription
and is the mediator of the majority of vitamin A’s func-
tions. In addition to the enzymes that synthesize RA, the
binding proteins transporting RA in the cytoplasm and the
nuclear retinoic acid receptors (RARs) that transduce the
signal, the capacity to switch off the RA signal is vital for
the action of the RA signaling pathway. This task is per-
formed by a subset of the cytochrome P450 family:
Cyp26a1, Cyp26b1 and Cyp26c1 (McCaffery and Simons
2007; Ross and Zolfaghari 2011). These microsomal
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enzymes oxidize RA to a range of metabolites including
4-hydroxy-RA, 18-hydroxy-RA, and 4-oxo-RA (Chithalen
et al. 2002). The essential need to turn off the RA signal is
illustrated by the embryonic or early postnatal lethality of
Cyp26a1 or Cyp26b1 null mutations. Loss of Cyp26a1
results in disruption of the posterior end of the embryo and
a caudal regression phenotype, as well as disorganization
of the normal patterning of the hindbrain (Abu-Abed et al.
2001). Null mutation of Cyp26b1 leads to defects in limb
development, among other abnormalities (Yashiro et al.
2004). Cyp26b1 is also required to control timing of
meiosis in germ cells of the developing mouse (Bowles
et al. 2006). In contrast to its counterparts, Cyp26c1 is
expressed to a lesser extent in the embryo and its loss in the
mouse has few effects, although mutation in the human
results in a range of facial skin defects (Slavotinek et al.
2013).
It is generally thought that the principal role for the Cyp26
enzymes in embryonic development is to limit the diffusion
of RA synthesized from vitamin A, creating regions of high
and low RA concentration. This controls the patterns of gene
expression that guide development (McCaffery and Simons
2007; Ross and Zolfaghari 2011). In the embryo, the
enzymes that synthesize RA from vitamin A (retinol) are
primarily retinol dehydrogenase 10 (Rdh10), oxidizing
retinol to retinaldehyde, which is then further oxidized to RA
by retinaldehyde dehydrogenases 1, 2 and 3 (Raldh1, 2, 3;
also known as Aldh1a1, 1a2, 1a3) (Napoli 2012). Swindell
and coworkers published a general observation that the
regions of RA synthesis in the embryo do not overlap with
the areas of RA degradation, which then creates the patterns
of RA distribution (Swindell et al. 1999). This implies that
RA predominantly acts as a paracrine factor in the devel-
oping embryo. Is this the case for its later function in the
adult? This new study examined such properties in the adult
brain and supports previous research indicating that RA can
have such a paracrine function in regions such as the rodent
hippocampus, where it performs a number of key functions
(Aoto et al. 2008; Chen and Napoli 2008). Surprisingly, it
was also found that RA can function in an autocrine manner
in the adult human brain, with co-expression of the RA
synthetic and catabolic enzymes in the same cell controlling
intracellular RA concentration and signaling. This reveals
an important aspect of the flexibility of RA signaling in the
nervous system.
Methods
Tissues
The experiments using human tissue were approved by the
Ethics Committee of the Universidade Metropolitana de
Santos, SP, Brazil, and by the Brazilian Health Research
Committee on April 4th 2011, under the number CONEP
16168, documents registered under the number
25000.169694/2010-18. Samples of liver, cerebellum and
caudal human hippocampus from six male individuals aged
55 years or less, who did not present any neurological or
psychiatric disease, were collected during post mortem
procedures. Brains from individuals whose death was
related to head trauma, extensive infection, or toxic, anoxic
or metabolic injuries were excluded from this study.
Samples from the hippocampus, measuring typically 5 mm
on each side, were fixed by immersion in 10 % phosphate-
buffered formalin within 24 h of death and processed into
paraffin wax blocks within the following 24 h. Other
samples were collected in RNAlater RNA Stabilization
Reagent (Qiagen) and stored at 4 C for qPCR or were
fresh-frozen on dry ice and stored at -80 C for analysis
by western blot.
All animal procedures were carried out in accordance
with UK Home Office regulations on laboratory animal use
according to the Animals (Scientific Procedures) Act 1986
and local ethics committee guidelines.
Detection of Cyp26 expression by polymerase chain
reaction (PCR)
Male and female adult rats were euthanized by overdose of
pentobarbital and their brains removed and placed on ice.
Medial cortex, lateral cortex, hippocampus, striatum, tha-
lamus, hypothalamus, olfactory bulb, cerebellum, choroid
plexus, and meninges were dissected and rapidly frozen on
dry ice. Total RNA was extracted from the tissues using a
Qiagen RNeasy kit. cDNA was synthesized from 500 ng of
RNA using a High Capacity RNA-to-cDNA kit (Applied
Biosystems) according to the manufacturer’s protocol.
Primers used were Cyp26a1 (NM_130408.2): For, TTC
GGG TGG CTC TGA AGA CT, Rev, CCT CTG GAT
GAA GCG ATG TAA AT. Cyp26b1 (NM_181087.2): For,
CCA GGA CTG TAT GCC CAT GA, Rev, CCA CTC
ACC AAC AAA AAG ACA AG. All PCR primers used in
this study were designed using PrimerBLAST (Ye et al.
2012), apart from rat Cyp26b1 primers, which were
designed and supplied by PrimerDesign Ltd. PCR products
were visualized by agarose gel electrophoresis and UV
transillumination.
Detection of Cyp26b1 expression by in situ
hybridization
The Cyp26b1 riboprobe template was prepared as previ-
ously described (Helfer et al. 2012) from a 925 bp cDNA
fragment corresponding to 2507–3431 bp of the mouse
Cyp26b1 cDNA sequence (NM_001177713.1). In situ
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hybridization was carried out as previously described using
35S-labeled riboprobe (Ross et al. 2009).
In vivo inhibition of CYP26 activity
The CYP26 inhibitor ser 2–7 (methyl 3-(1H-imidazol-
1-yl)-2,2-dimethyl-3-(4-(naphthalen-2-ylamino)phenyl)
propanoate; Gomaa et al. 2011) was dissolved at 8 mg/ml
in DMSO. Immediately before use, the ser 2–7 solution
was mixed with an equal volume of sterile phosphate-
buffered saline (PBS) to give a 4 mg/ml solution. For
measurement of retinoic acid levels in tissue, female
C57BL/6 mice between 8 and 12 weeks of age received a
single intraperitoneal (IP) injection of 10 mg/kg ser 2–7.
Control animals received an intraperitoneal (IP) injection
of an equivalent volume of 1:1 PBS/DMSO. Treated ani-
mals were euthanized using pentobarbital 2, 6 or 18 h after
ser 2–7/vehicle administration and the hippocampi rapidly
dissected on ice and snap frozen on dry ice. Samples were
stored at -80 C before use.
For cell proliferation studies, RARE-LacZ mice (Rossant
et al. 1991) between 8 and 12 weeks of age received 10 mg/
kg ser 2–7 by IP injection once every 24 h for 3 days.
Injections were carried out in the morning on each day. On
the third day, immediately after the last ser 2–7 treatment, all
mice received three additional injections, 2 h apart, of
50 mg/kg bromodeoxyuridine (BrdU) in PBS. 2 h after the
final BrdU injection, the mice were perfused transcardially
first with PBS, then 4 % paraformaldehyde (PFA) in phos-
phate buffer. The brain was removed and placed at 4 C in
PFA overnight, then transferred to 30 % sucrose at 4 C.
Measurement of RA levels in tissue
A reporter gene assay was used as described elsewhere
(Helfer et al. 2012) to measure levels of RA activity in the
hippocampus of ser 2–7-injected mice. Sil-15 cells carrying
a LacZ reporter gene driven by multiple retinoic acid
response elements (Wagner et al. 1992) were maintained in
DMEM/F-12 containing 10 % fetal calf serum and 0.8 mg/
ml G418. Hippocampi from ser 2–7-/vehicle-injected mice
were homogenized under low light conditions in an ice-
cold 2:1 mix of isopropanol/ethanol containing 1 mg/ml
butylated hydroxytoluene to reduce oxidation. Homo-
genates were centrifuged at 13,000 rpm for 5 min at 4 C.
The supernatant was diluted 1:50 in DMEM/F-12 and
added to a 96-well plate containing Sil-15 cells followed by
overnight incubation at 37 C, 5 % CO2. The cells were
fixed in 1 % glutaraldehyde and b-galactosidase activity
was quantified using X-gal and colorimetric analysis. The
response of Sil-15 cells to tissue extracts was compared to
a standard curve plotted from the response to a series of
known RA concentrations from 1 lM to 1 pM.
Immunohistochemical measurement of cell
proliferation using bromodeoxyuridine (BrdU)
Perfused mouse brains were cut into 40 lm coronal sec-
tions using a cryostat. Sections were washed in PBS and
then incubated in 1 M hydrochloric acid for 30 min at
47 C, followed by further washes in PBS. Sections were
then blocked in PBS containing 10 % goat serum and
0.3 % Triton X-100 for 2 h at room temperature and
incubated overnight at 4 C in anti-BrdU antibody (AbD
Serotec) diluted 1:200 in blocking buffer. After washing in
PBS containing 0.3 % Triton X-100 (PBST), sections were
incubated in fluorescent anti-rat secondary antibody (1:300
in blocking buffer; Jackson ImmunoResearch) for 2 h at
room temperature. Following further washes in PBST,
sections were mounted onto slides using mounting medium
containing bisbenzimide. Images were obtained by fluo-
rescence microscopy and BrdU incorporation was quanti-
fied by counting of the number of BrdU-positive cells in
every 12th section from each brain (sections were
approximately 480 lm apart). The ratio between the total
number of BrdU-positive cells in the supra- and
infrapyramidal blades was calculated. Only cells within
two cell diameters of the subgranular zone (SGZ; Kuhn
et al. 1997) were included in cell counts.
Quantitative PCR
RNA was extracted from samples of human hippocampus,
cerebellum and liver and cDNA synthesised as described
above. GAPDH was used as a reference gene. Primer
sequences: CYP26A1 (NM_000783.3, NM_057157.2): For,
CAC CGT ACG GGT GAT GGG CG, Rev, GCT GGC
CAG TGG ACC GAC AC; CYP26B1 (NM_001277742.1,
NM_019885.3): For, ACC GGC CAC TGG CTG CTG,
Rev, ACG TTG ATG GCC TCG GGG TG. GAPDH
(NM_002046.5): For, TCT TTT GCG TCG CCA GCC
GA, Rev, AGT TAA AAG CAG CCC TGG TGA CCA.
Western blotting
Human hippocampus was homogenized in 0.01 M phos-
phate buffer, pH 7.0, containing a broad spectrum protease
inhibitor cocktail (Roche) using mechanical homogeniza-
tion and three freeze–thaw cycles. Homogenates were
centrifuged for 10 min at 12,000 rpm at 4 C. Total protein
levels in each sample were quantified using the bicin-
choninic acid assay (Pierce) and 50 lg protein was loaded
per lane of a 12 % SDS-PAGE mini-gel. After separation,
the proteins were transferred onto a Hybond-ECL nitro-
cellulose membrane (GE Healthcare) using a Mini Trans-
Blot Cell (Bio-Rad) and equal loading was confirmed with
Ponceau-S (Sigma). Membranes were blocked for 1 h at
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room temperature in TBS containing 0.05 % Tween-20
(TBST) and 5 % skimmed milk and then probed with
mouse anti-CYP26A1 antibody (1:1000 in blocking buffer;
Vertebrate Antibodies) at 4 C overnight. Membranes were
washed in TBST and then incubated in HRP-conjugated
anti-rabbit secondary antibody (1:3000; Jackson
ImmunoResearch) for 1 h at room temperature. The
membranes were washed again in TBST and antibody
binding visualized by enhanced chemiluminescence (ECL;
Millipore) and exposure to X-ray film (Thermo).
Detection of CYP26 in the human brain
by immunohistochemistry
Formalin-fixed samples of human hippocampus were pro-
cessed into paraffin wax blocks and sectioned at 7 lm.
Sections were mounted on TruBond 380 slides (Electron
Microscopy Sciences) and dried overnight at 37 C. Sec-
tions were dewaxed in xylene and rehydrated through a
series of decreasing ethanol concentrations (100, 95, 80
and 70 %). The slides were washed briefly in PBS, pH 7.4,
and then boiled for 10 min in sodium citrate buffer, pH 6.0.
After cooling, slides were washed in PBS containing 1 %
Tween-20 (Sigma) and 1 % pooled human serum (Bio-
Sera), hereafter referred to as PBS(HS). Tissue sections
were incubated for 1 h at room temperature in blocking
solution consisting of PBS, pH 7.4, containing 0.3 %
Tween-20, 5 % goat serum, 5 % bovine serum albumin and
5 % pooled human serum (Makitie et al. 2013). Sec-
tions were then incubated with primary antibodies (chicken
anti-MAP2, 1:400, Abcam; goat anti-RALDH2, 1:1000,
Santa Cruz; mouse anti-CYP26A1, 1:50 Vertebrate Anti-
bodies; goat anti-Iba1, 1:300, Abcam) diluted in blocking
solution and incubated overnight at 4 C. After incubation,
the slides were washed in PBS(HS). The tissue was then
incubated for 1 h at room temperature in appropriate flu-
orescent secondary antibodies (Jackson ImmunoResearch)
diluted 1:300 in PBS(HS). Slides were washed in PBS(HS)
and incubated for 1 min with 10 % Sudan black (Acros
Organics) in 70 % isopropanol to reduce auto-fluorescence
(Schnell et al. 1999; Neumann and Gabel 2002). The slides
were then thoroughly washed in distilled water and
mounted with mounting medium containing bisbenzimide
(Sigma). The quantitation of number of labeled cells was
based on counts of between 60 and 90 cells.
SH-SY5Y treatment with vitamin A and retinoic
acid
SH-SY5Y neuroblastoma cells were maintained in DMEM/
F12 containing 10 % fetal calf serum and penicillin/
streptomycin and Glutamax (Invitrogen). Cells were trea-
ted with either 0.35 lM retinol and 0.3 lM retinyl acetate
or 1 lM retinoic acid for 8 or 24 h with serum replaced
with B27 supplement (Gibco). Retinoic acid was dissolved
in DMSO and so this was added at an equivalent concen-
tration (0.1 %) to wells containing untreated control cells.
Following treatment, total RNA was extracted from the
cells, cDNA synthesized and qPCR performed as described
above using the following primers: RALDH2
(NM_003888.3, NM_170696.2, NM_170697.2,
NM_001206897.1): For, CAC TGA GCA GGG TCC CCA
GAT TGA, Rev, AAC CCC TTT CGG CCC AGT CCT;
RALDH3 (NM_000693.3, NM_001293815.1): For, CGC
AAC CTG GAG GTC AAG TTC ACC, Rev, AGC CTT
GTC CAC GTC GGG CTT A. GAPDH was used as a
reference gene.
Results
Cyp26 transcript expression in the adult rodent
brain
Cyp26a1 gene expression is reported to be weak in the
adult mouse brain (Abu-Abed et al. 2002) and PCR
analysis of the adult rat brain (Fig. 1a) shows similar
weak expression, with almost no Cyp26a1 transcript
detected in the hippocampus, hypothalamus, cerebellum
and olfactory bulb. Some expression was detected in the
meninges, striatum, thalamus and cerebral cortex
(Fig. 1a). Dissection of tissue to avoid any contaminating
meninges or choroid plexus found the levels in striatum
and thalamus were low, and the choroid plexus itself had
little expression, but the moderate amounts of Cyp26a1 in
the cortex were the same whether lateral or medial regions
were dissected from caudal cortex (Fig. 1b). Cyp26b1, in
contrast, is more strongly expressed and widely distributed
in the rat brain than Cyp26a1 and is particularly high in
the cerebellum and meninges while also present in the
striatum, olfactory bulb, hippocampus, hypothalamus,
thalamus and cerebral cortex (Fig. 1a), extending an ear-
lier description of Cyp26b1 in the hippocampus and
amygdala (Abu-Abed et al. 2002). In situ hybridization
showed that, although Cyp26b1 is widely distributed in
the rat forebrain, it has a patterned rather than homoge-
neous distribution and is strongly expressed in subregions
of the cortex, amygdala, striatum and hippocampus
(Fig. 1c–e). The distribution of Cyp26b1 suggests that this
catabolic enzyme may play a role to pattern the distribu-
tion of RA in the adult brain, similar to its function in the
developing embryo.
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A role for Cyp26b1 in patterning a paracrine action
of retinoic acid in the rodent hippocampus
In the dentate gyrus of the hippocampus (Fig. 2a), we have
previously proposed that RA diffuses ventrally from the
meninges to create a gradient of high RA in the
infrapyramidal (lower) blade compared to suprapyramidal
(upper) blade, which leads to a disparity in the rate of cell
proliferation controlled by RA between the blades
(Goodman et al. 2012). The location of Cyp26b1 between
these blades will reduce diffusion of RA (Fig. 2a) and
increase the steepness of the gradient. If this is the case
then Cyp26b1 inhibition should reduce the difference in
cell proliferation between the two blades. To test this
hypothesis, we investigated the effect of Cyp26 inhibition
on the rate of cell proliferation in the two blades of the
dentate gyrus in the mouse (Goodman et al. 2012), treating
mice with a new Cyp26 inhibitor, ser 2–7 (Fig. 2b), which
Fig. 1 Cyp26a1 and Cyp26b1 transcript expression in the adult rat
brain. a RT-PCR of dissected rat tissue showed relatively weak bands
for Cyp26a1 in meninges, striatum, thalamus and cerebral cortex.
Cyp26b1 in contrast was stronger and more widespread with
expression in striatum, olfactory bulb, hippocampus, hypothalamus,
thalamus and cerebral cortex. b Expression of Cyp26a1 in the rat
brain was unexpected given that it is reported to be absent from the
mouse brain. Rat tissues were thus dissected to avoid any contam-
inating meninges or choroid plexus as potential extraneous sources of
the enzyme but Cyp26a1 transcript was still detected in medial and
lateral cortex and weakly present in the striatum. c Cyp26b1, the
predominant Cyp26 in the rat brain, was examined by in situ
hybridization and was present in localized regions of the cortex,
amygdala, striatum and hippocampus. Cb cerebellum, ChP choroid
plexus, Cx cortex, Hyp hypothalamus, Hipp hippocampus, LCx lateral
cortex, MCx medial cortex, Men meninges, OB olfactory bulb, Str
striatum, Thal thalamus
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has nearly 200-fold greater affinity for Cyp26 than previous
inhibitors such as liarozole (Gomaa et al. 2011). Animals
were sacrificed 2, 6 or 18 h after receiving a single IP
injection of 10 mg/kg ser 2–7 or vehicle and the RA levels
in the hippocampus analyzed using a cell-based bioassay.
Treatment with ser 2–7 significantly increased
hippocampal RA levels after 2–6 h (P\ 0.05, ANOVA
followed by post hoc Tukey’s HSD test). By 18 h post-
injection, RA levels in the hippocampus of ser 2–7-treated
mice had almost returned to control levels (Fig. 2b).
To examine the influence of this Cyp26 inhibitor on cell
proliferation in the upper and lower blades of the dentate
Fig. 2 Cyp26b1 is expressed in the hilus of the dentate gyrus and
inhibition of Cyp26 alters the pattern of cell proliferation in the
dentate gyrus. a In situ hybridization of Cyp26b1 illustrates expres-
sion of the catabolic enzymes in the hilus between the infrapyramidal
(lower) and suprapyramidal (upper) blades of the dentate gyrus.
b Relative levels of RA in the hippocampus 2, 6 and 18 h after
injection of ser 2–7 (structure shown top right). RA levels were
significantly increased 2 h post-injection, returning to pre-treatment
levels by 18 h. * P\ 0.05, mean ± SEM, n = 3. Cell proliferation
in the subgranular zone (SGZ) of the dentate gyrus was then
quantified after 3 days of treatment with ser 2–7. C, d Change in cell
proliferation was determined in the SGZ by counting of BrdU-labeled
cells with higher magnification views of individual cells shown in c’
and d’. e Quantification of BrdU-labeled cells in the SGZ showed that
the number of BrdU-labeled cells in the suprapyramidal blade fell
with ser 2–7 treatment, although not significantly. f When the ratio of
BrdU-positive cells in the suprapyramidal versus the infrapyramidal
blades of the dentate gyrus was determined it was significantly
different from one in the control, vehicle-treated hippocampus
(greater labeling in the suprapyramidal blade) but was not signifi-
cantly different from one after ser 2–7 treatment (similar labeling in
infrapyramidal and suprapyramidal blades)
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gyrus, mice were treated with ser 2–7 (10 mg/kg) or
vehicle once a day for 3 days with the final dose injected
6 h before killing. Beginning 6 h before killing, animals
also received 3 injections of the thymidine analog bro-
modeoxyuridine (BrdU) 2 h apart.
It was hypothesized that inhibition of Cyp26 by ser 2–7
would reduce the gradient of RA between the two blades
and equalize cell proliferation between them. Proliferating
cells were identified by incorporation of BrdU and cell
proliferation was quantified by counting BrdU-positive
nuclei (Fig. 2c, d). Ser 2–7 treatment decreased the number
of BrdU-labeled cells per dentate gyrus, although this
decline was not significant by ANOVA (P = 0.08,
Fig. 2e). However, when analyzed as the ratio difference,
significantly more BrdU-positive cells were observed in the
upper blade of the dentate gyrus of vehicle-treated control
animals than in the lower blade (Fig. 2f, ratio of
suprapyramidal BrdU-positive cells/infrapyramidal BrdU-
positive cells = 1.96; significantly different from a ratio of
1 by one-sample t test, P\ 0.02, n = 5). Inhibition of
Cyp26 function using ser 2–7 resulted in a ratio between
the two blades closer to one (Fig. 2e, suprapyramidal/in-
frapyramidal BrdU ratio = 1.36; not significantly higher
than a ratio of 1 by one-sample t test). The effect of ser 2–7
on cell proliferation is likely to be due to inhibition of
Cyp26b1 activity in the region between the blades,
resulting in more RA reaching the suprapyramidal blade.
This may be combined with a systemic increase in RA due
to whole-body/systemic inhibition of Cyp26, creating
greater homogeneity of RA across the hippocampus.
Overall this leads to suppression of RA catabolism in both
blades and a ratio of cell proliferation between blades
closer to one. These results point to a paracrine action of
RA in the blades of dentate gyrus, where it acts at a dis-
tance from its site of synthesis in the meninges, as we have
previously proposed (Goodman et al. 2012).
CYP26 expression in the human brain: is paracrine
signaling the only signaling route for RA
in the brain?
The greater size of the human compared to the rodent
brain and the larger fiber tracts and hence the larger
amount of lipid in the form of myelin may mean that
establishing robust gradients of RA across, for instance,
the dentate gyrus by diffusion from an external source is
much harder. qPCR indicated that both CYP26A1 and
CYP26B1 were present in the human hippocampus and
cerebellum at comparable levels to that in liver (Fig. 3a).
An antibody against CYP26A1 was identified that gave a
single major band by western blot (Fig. 3b) of similar
molecular weight to the 56 kDa previously reported
(Topletz et al. 2012). Using this antibody for
immunohistochemistry, it was found that, unlike the rat
and mouse, MAP2-positive neurons in the human dentate
gyrus express CYP26A1 (Fig. 4a, 95.0 % of MAP2-pos-
itive cells expressing CYP26A1). In contrast, GFAP
positive astrocytes in the dentate gyrus (Fig. 4b) were
negative for CYP26A1, as were the same cell type in
CA1 of the hippocampus seen at higher magnification
(Fig. 4c). Iba1-positive microglia, which in culture
express the catabolic enzyme (Hellmann-Regen et al.
2013), were also negative for CYP26A1 (Fig. 4d). Dou-
ble-labeling of human brain sections with antibodies
against CYP26A1 and one of the RA synthetic enzymes,
RALDH2, identified a further difference from the rodent
brain as all cells in both the dentate gyrus and cerebellum
co-expressed CYP26A1 and RALDH2 (Fig. 4e, f).
Widespread co-expression of the synthetic and catabolic
enzymes in hippocampal neurons, which are also known
to express RA receptors (Fragoso et al. 2012), suggests
that RA has an autocrine function in these cells rather
than diffusing to neurons from an external source, as
occurs in the rodent dentate gyrus (Goodman et al. 2012).
Retinoid-regulated synthetic and catabolic enzyme
expression in a human neuroblastoma cell line
If human neurons can modulate intracellular RA levels by
expressing both RA synthetic and catabolic enzymes then it
would be expected that expression of the genes encoding
the catabolic and synthetic enzymes may be altered in
response to changes in vitamin A/RA levels, in order to
rebalance retinoid levels. To explore this, SH-SY5Y human
neuroblastoma cells were treated with RA or retinol (?
retinyl palmitate) for 8 or 24 h. Both CYP26A1 (Fig. 5a, an
over 600-fold increase but not significant because of a high
variability in response) and CYP26B1 (Fig. 5b, P = 0.042,
ANOVA with post hoc Tukey’s test) were rapidly induced
by RA, as has been reported previously (Ray et al. 1997),
providing a mechanism by which excess RA can be
removed. Both were also induced after 24 h of RA treat-
ment, although only CYP26B1 significantly (Fig. 5d,
P = 0.0005, ANOVA with post hoc Tukey’s test). Addi-
tion of retinol to the medium had no effect on these cata-
bolic enzymes (Fig. 5a–d). The RA synthetic enzymes
RALDH2 and RALDH3 were also examined (an additional
family member, RALDH1, was absent from SH-SY5Y
cells, results not shown). In contrast to the catabolic
enzymes, RALDH2 and RALDH3 did not respond to RA
(Fig. 5e–h). However, the presence of retinol after 24 h
triggered a significant repression of RALDH3 (Fig. 5h,
P = 0.033, ANOVA with post hoc Tukey’s test), poten-
tially reducing RA synthesis when vitamin A levels are
high but enabling these neurons to make more efficient use
of reduced amounts when vitamin A levels are low.
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Discussion
Cyp26a1 and Cyp26b1 are the primary enzymes for RA
catabolism in the body (McCaffery and Simons 2007; Ross
and Zolfaghari 2011). Much initial attention was directed
to their role in the developing embryo (Abu-Abed et al.
2001; Yashiro et al. 2004) where a key element to their
function arose from their spatial distribution—expression
in regions adjacent to areas of high RA synthesis, limiting
diffusion to create precise patterns of RA concentration.
The distribution of retinoic acid synthetic and catabolic
enzymes in the embryo was always found to be comple-
mentary, with RA diffusing from synthetic tissue and act-
ing as a paracrine factor on tissues distant from this source
(Swindell et al. 1999). Initial findings in the adult rodent
brain pointed to a similar paracrine action for RA.
In the rodent brain the predominant source of RA is the
meninges surrounding the brain (Goodman et al. 2012). In situ
hybridization shows the expression of the catabolic enzyme
Cyp26b1 in subregions of the brain. Expression is strong in
several areas of the forebrain, presumably limiting the con-
centration of RA in these regions. Such regions of high
Cyp26b1 expression include the lateral and medial cortex, but
it is absent from the upper layers of the medial cortex where
the synthetic enzyme Raldh3 is present, potentially setting up
regions of RA-regulated plasticity in the cortex (Wagner et al.
2006). There are limited regions of RA signaling in the
amygdala where it is also proposed to delineate zones of
plasticity (Thompson Haskell et al. 2002) and these regions
would be assumed to be complementary to the intense areas of
Cyp26b1 expression in subregions of the amygdala. These
patterns of Cyp26 expression, separated from regions of RA
synthesis, suggest a paracrine action of RA.
This paracrine function for RA is exemplified by its role
in control of cell proliferation in neurogenic regions in the
rodent hippocampus. In situ hybridization shows strong
Cyp26b1 expression in cells of the hilus between the two
blades of the dentate gyrus in the hippocampus. We pre-
viously proposed that this reduces the amount of RA that
can diffuse from the meninges adjacent to the infrapyra-
midal blade of the dentate gyrus to reach the upper,
suprapyramidal blade. We have previously shown that this
asymmetry in RA between the blades of the dentate gyrus
contributes to the difference in rates of cell proliferation in
the subgranular zones of the two blades. Neurogenesis in
these regions is crucial for several aspects of hippocampus-
dependent memory, including pattern separation (Schmidt
et al. 2012), the process that reduces confusion of old
memories with new. Differences in the functions of the two
blades are also proposed to be important in the pattern
separation task of the dentate gyrus (Schmidt et al. 2012).
Normally the upper, suprapyramidal blade has significantly
higher levels of cell proliferation than the lower blade with
a two-fold ratio between the blades. Treatment of mice
with the Cyp26 inhibitor ser 2–7 resulted in equalization of
the ratio of BrdU incorporation between the upper and
lower blades. In the normal animal, this may have a
detrimental effect on pattern separation aspects of memory.
Although there may be a detrimental effect under nor-
mal circumstances, the effectiveness of ser 2–7 to increase
RA in the hippocampus may have some benefit in disorders
where RA signaling is believed to decline, such as Alz-
heimer’s disease. Several recent articles and reviews have
proposed RA treatment for this disorder because of its
action to promote the non-amyloidogenic pathway of
amyloid precursor protein cleavage as well as its anti-in-
flammatory properties, promotion of cholinergic transmis-
sion, reduction of intracellular cholesterol and cell-
protective properties (Ono and Yamada 2012; Sodhi and
Singh 2014). Increasing hippocampal RA may be
Fig. 3 Expression of CYP26A1
and CYP26B1 in the human
brain. a qPCR analysis of
CYP26A1 and CYP26B1
showed expression in both the
human hippocampus and
cerebellum at levels
approximately half of that in the
human liver. b Western blotting
for CYP26A1 protein in the
human hippocampus identifies a
prominent band of
approximately 54 kDa
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particularly beneficial because RA levels are declining in
the aging hippocampus (Etchamendy et al. 2001). How-
ever, rather than administration of RA itself, the use of
Cyp26 inhibitors to raise endogenous RA is a route less
likely to result in excessively high and potentially dam-
aging amounts of RA in the brain. Further, this method
avoids the problem of retinoid resistance where addition of
RA induces the Cyp26 enzymes (Ray et al. 1997), limiting
the efficacy of RA-based treatments over time.
The study of CYP26 in the human, versus rodent, brain has
revealed a wider distribution of the catabolic enzymes in the
human, suggesting a more widespread action. We have previ-
ously shown that RA signaling in the human brain differed from
that of the rodent with the RA synthetic enzymes RALDH1, 2
and 3 expressed not just in the surrounding meninges but also in
many neurons (Fragoso et al. 2012), suggesting a higher
requirement for RA in the human brain compared to the rodent.
In this study qPCR confirmed expression of bothCYP26A1 and
CYP26B1 in the human brain. The methods employed did not
provide an absolute comparison of the relative amounts but
previous quantitative studies (Topletz et al. 2012) found about
fivefold higher levels of CYP26B1 than CYP26A1 in the cere-
bral cortex, but in the cerebellum CYP26B1 predominated by
over 100-fold.
Given the expression of CYP26A1 and CYP26B1 tran-
scripts in the human brain we investigated the distribution
of CYP26A1 protein, for which we selected an antibody
which gave only a single band by western blotting.
Immunohistochemistry indicated that, like RALDH2
(Fragoso et al. 2012), CYP26A1 was present in neurons.
Fig. 4 Immunohistochemistry of CYP26A1 in the human hippocam-
pus and cerebellum. a Double-labeling of cells with antibodies to the
neuron-specific protein MAP2 and CYP26A1 showed expression of
this catabolic enzyme in neurons of the dentate gyrus. In contrast,
double-labeling of cells with antibodies to GFAP showed that b glia
in the dentate gyrus did not express CYP26A1 and c cells with
astrocyte morphology in the CA1 hippocampal subfield also lacked
CYP26A1. d Similarly, cells labeled with an antibody against the
microglia-specific IBA1 did not express CYP26A1. e, f Double-
labeling of cells for both CYP26A1 and RALDH2 showed that cells
in the dentate gyrus (e) and cerebellum (f, Purkinje cells) co-
expressed these enzymes
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Comparison of CYP26A1 and RALDH2 expression indi-
cated a high degree of colocalization in granule neurons of
the hippocampus and Purkinje neurons of the cerebellum.
We have previously demonstrated that these neurons
express RA receptors and their co-expression of both RA
synthetic and catabolic enzymes implies the capacity for
autocrine RA signaling with the ability to both upregulate
and downregulate the RA signal. If this were the case it
would be expected that the synthetic and catabolic enzymes
would respond to relative levels of RA and its retinol
precursor. Expression of the genes encoding the RALDH
and CYP26 enzymes was examined in the SH-SY5Y
neuroblastoma cell line. As previously reported in many
studies on non-neural cells [for example (Ray et al. 1997;
Zhang et al. 2010)], RA rapidly induces CYP26A1 and
CYP26B1, although this induction is attenuated by 24 h. In
contrast, transcript levels of the synthetic enzymes
RALDH2 and RALDH3 were not influenced by RA; how-
ever, when retinol levels were increased there was a sig-
nificant fall in RALDH3 transcript after 24 h. Such
feedback control by the substrate for RA has not been
previously described for the synthetic enzymes and sug-
gests a mechanism that could help maintain local RA levels
in the brain relatively constant by helping to prevent wide
fluctuations.
Summary
In the rodent brain RA can, as a paracrine signaling factor,
diffuse across tissues to control localized gene expression
as it does in the embryo. The Cyp26 catabolic enzymes,
expressed in cells distant from the site of synthesis, help to
regulate the pattern of RA diffusion. This separation
between sites of synthesis and catabolism occurs in other
adult rodent tissues such as the uterus (Ma et al. 2012).
However, in human neurons RA can have a different,
autocrine, function that is restrained by CYP26. Neurons,
but not glia, in the adult human hippocampus and cere-
bellum express both CYP26A1 and RALDH2 which
together can modulate the balance of RA within single
cells. This contrasts with the embryo and adult rodent brain
Fig. 5 Regulation by RA and retinol of CYP26 catabolic and RALDH
synthetic enzymes transcript in SH-SY5Y cells. a, b Eight hours of
RA treatment induced both CYP26A1 (a) and CYP26B1 expression
(b, P = 0.042, ANOVA with Tukey’s post hoc test) whereas retinol
had no effect. c, d Twenty-four hours of RA treatment similarly
induced both CYP26A1 (c) and CYP26B1 (d, P = 0.0005, ANOVA
with Tukey’s post hoc test) while retinol had no effect. e, f Eight
hours of retinol or RA treatment did not result in significant change in
RALDH2 and RALDH3. g, h In contrast, RALDH3 expression
decreased significantly 24 h after retinol treatment (h, P = 0.033,
ANOVA with Tukey’s post hoc test)
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in which the synthetic and catabolic enzymes control the
balance of RA broadly across tissues. This would be the
first time that an autocrine RA signaling system, with the
capacity to switch on and off the RA signal in individual
neurons, has been proposed in the human brain.
Acknowledgments Funding was provided by the Wellcome Trust
grant WT081633MA-NCE and Biological Sciences Research Council
Grant BB/K001043/1. Prof Fragoso is the recipient of a Post Doctoral
Science without Borders grant from the Brazilian National Council
for Scientific and Technological Development (CNPq, 237450/2012-
7).
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
Abu-Abed S, Dolle P, Metzger D, Beckett B, Chambon P, Petkovich
M (2001) The retinoic acid-metabolizing enzyme, CYP26A1, is
essential for normal hindbrain patterning, vertebral identity, and
development of posterior structures. Genes Dev 15:226–240
Abu-Abed S, MacLean G, Fraulob V, Chambon P, Petkovich M,
Dolle P (2002) Differential expression of the retinoic acid-
metabolizing enzymes CYP26A1 and CYP26B1 during murine
organogenesis. Mech Dev 110:173–177
Aoto J, Nam CI, Poon MM, Ting P, Chen L (2008) Synaptic signaling
by all-trans retinoic acid in homeostatic synaptic plasticity.
Neuron 60(2):308–320
Bowles J, Knight D, Smith C, Wilhelm D, Richman J, Mamiya S,
Yashiro K, Chawengsaksophak K, Wilson MJ, Rossant J,
Hamada H, Koopman P (2006) Retinoid signaling determines
germ cell fate in mice. Science 312:596–600
Chen N, Napoli JL (2008) All-trans-retinoic acid stimulates transla-
tion and induces spine formation in hippocampal neurons
through a membrane-associated RARalpha. FASEB J
22(1):236–245
Chithalen JV, Luu L, Petkovich M, Jones G (2002) HPLC-MS/MS
analysis of the products generated from all-trans-retinoic acid
using recombinant human CYP26A. J Lipid Res
43(7):1133–1142
Etchamendy N, Enderlin V, Marighetto A, Vouimba RM, Pallet V,
Jaffard R, Higueret P (2001) Alleviation of a selective age-
related relational memory deficit in mice by pharmacologically
induced normalization of brain retinoid signaling. J Neurosci
21(16):6423–6429
Fragoso YD, Shearer KD, Sementilli A, de Carvalho LV, McCaffery
PJ (2012) High expression of retinoic acid receptors and
synthetic enzymes in the human hippocampus. Brain Struct
Funct 217(2):473–483
Gomaa MS, Bridgens CE, Aboraia AS, Veal GJ, Redfern CP,
Brancale A, Armstrong JL, Simons C (2011) Small molecule
inhibitors of retinoic acid 4-hydroxylase (CYP26): synthesis and
biological evaluation of imidazole methyl 3-(4-(aryl-2-ylami-
no)phenyl)propanoates. J Med Chem 54(8):2778–2791
Goodman T, Crandall JE, Nanescu SE, Quadro L, Shearer K, Ross A,
McCaffery P (2012) Patterning of retinoic acid signaling and cell
proliferation in the hippocampus. Hippocampus
22(11):2171–2183
Helfer G, Ross AW, Russell L, Thomson LM, Shearer KD, Goodman
TH, McCaffery PJ, Morgan PJ (2012) Photoperiod regulates
vitamin A and Wnt/beta-catenin signaling in F344 rats.
Endocrinology 153(2):815–824
Hellmann-Regen J, Kronenberg G, Uhlemann R, Freyer D, Endres M,
Gertz K (2013) Accelerated degradation of retinoic acid by
activated microglia. J Neuroimmunol 256(1–2):1–6
Kuhn HG, Winkler J, Kempermann G, Thal LJ, Gage FH (1997)
Epidermal growth factor and fibroblast growth factor-2 have
different effects on neural progenitors in the adult rat brain.
J Neurosci 17(15):5820–5829
Ma JJ, Han BC, Yang Y, Peng JP (2012) Retinoic acid synthesis and
metabolism are concurrent in the mouse uterus during peri-
implantation. Cell Tissue Res 350(3):525–537
Makitie LT, Kanerva K, Polvikoski T, Paetau A, Andersson LC
(2013) Brain neurons express ornithine decarboxylase-activating
antizyme inhibitor 2 with accumulation in Alzheimer’s disease.
Brain Pathol 20(3):571–580
McCaffery P, Simons C (2007) Prospective teratology of retinoic acid
metabolic blocking agents (RAMBAs) and loss of CYP26
activity. Curr Pharm Des 13(29):3020–3037
Napoli JL (2012) Physiological insights into all-trans-retinoic acid
biosynthesis. Biochim Biophys Acta 1821(1):152–167
Neumann M, Gabel D (2002) Simple method for reduction of
autofluorescence in fluorescence microscopy. J Histochem
Cytochem 50(3):437–439
Ono K, Yamada M (2012) Vitamin A and Alzheimer’s disease.
Geriatri Gerontol Int 12(2):180–188
Ray W, Bain G, Yao M, Gottlieb DI (1997) CYP26, a novel
mammalian cytochrome P450, is induced by retinoic acid and
defines a new family. J Biol Chem 272:18702–18708
Ross AC, Zolfaghari R (2011) Cytochrome P450 s in the regulation
of cellular retinoic acid metabolism. Annu Rev Nutr 31:65–87
Ross AW, Johnson CE, Bell LM, Reilly L, Duncan JS, Barrett P,
Heideman PD, Morgan PJ (2009) Divergent regulation of
hypothalamic neuropeptide Y and agouti-related protein by
photoperiod in F344 rats with differential food intake and
growth. J Neuroendocrinol 21(7):610–619
Rossant J, Zirngibl R, Cado D, Shago M, Gigue`re V (1991)
Expression of a retinoic acid response element-hsplacZ trans-
gene defines specific domains of transcriptional activity during
mouse embryogenesis. Genes Dev 5:1333–1344
Schmidt B, Marrone DF, Markus EJ (2012) Disambiguating the
similar: the dentate gyrus and pattern separation. Behav Brain
Res 226(1):56–65
Schnell SA, Staines WA, Wessendorf MW (1999) Reduction of
lipofuscin-like autofluorescence in fluorescently labeled tissue.
J Histochem Cytochem 47(6):719–730
Slavotinek AM, Mehrotra P, Nazarenko I, Tang PL, Lao R, Cameron
D, Li B, Chu C, Chou C, Marqueling AL, Yahyavi M, Cordoro
K, Frieden I, Glaser T, Prescott T, Morren MA, Devriendt K,
Kwok PY, Petkovich M, Desnick RJ (2013) Focal facial dermal
dysplasia, type IV, is caused by mutations in CYP26C1. Hum
Mol Genet 22(4):696–703
Sodhi RK, Singh N (2014) Retinoids as potential targets for
Alzheimer’s disease. Pharmacol Biochem Behav 120:117–123
Swindell EC, Thaller C, Sockanathan S, Petkovich M, Jessell TM,
Eichele G (1999) Complementary domains of retinoic acid
production and degradation in the early chick embryo. Dev Biol
216(1):282–296
Thompson Haskell G, Maynard TM, Shatzmiller RA, Lamantia AS
(2002) Retinoic acid signaling at sites of plasticity in the mature
central nervous system. J Comp Neurol 452(3):228–241
Brain Struct Funct (2016) 221:3315–3326 3325
123
Topletz AR, Thatcher JE, Zelter A, Lutz JD, Tay S, Nelson WL,
Isoherranen N (2012) Comparison of the function and expression
of CYP26A1 and CYP26B1, the two retinoic acid hydroxylases.
Biochem Pharmacol 83(1):149–163
Wagner M, Han B, Jessell TM (1992) Regional differences in retinoid
release from embryonic neural tissue detected by an in vitro
reporter assay. Development 116:55–66
Wagner E, Luo T, Sakai Y, Parada LF, Drager UC (2006) Retinoic
acid delineates the topography of neuronal plasticity in postnatal
cerebral cortex. Eur J Neurosci 24(2):329–340
Yashiro K, Zhao X, Uehara M, Yamashita K, Nishijima M, Nishino J,
Saijoh Y, Sakai Y, Hamada H (2004) Regulation of retinoic acid
distribution is required for proximodistal patterning and out-
growth of the developing mouse limb. Dev Cell 6:411–422
Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL
(2012) Primer-BLAST: a tool to design target-specific primers
for polymerase chain reaction. BMC Bioinformatics 13:134
Zhang Y, Zolfaghari R, Ross AC (2010) Multiple retinoic acid
response elements cooperate to enhance the inducibility of
CYP26A1 gene expression in liver. Gene 464(1–2):32–43
3326 Brain Struct Funct (2016) 221:3315–3326
123
